



**TMC LIFE SCIENCES BERHAD**  
**Company no. 200301021989 (624409-A)**  
**(Incorporated in Malaysia)**

**UNAUDITED INTERIM FINANCIAL REPORT  
FOR THE FINANCIAL QUARTER ENDED  
31 DECEMBER 2025**

**Contact**

Level 11, No.11, Jalan Teknologi,  
Taman Sains Selangor 1, PJU 5,  
Kota Damansara  
47810 Petaling Jaya, Selangor D.E.

Tel: +603 6287 1111  
Fax: +603 6287 1212

[www.tmclife.com](http://www.tmclife.com)

**TMC LIFE SCIENCES BERHAD**  
**Company no. 200301021989 (624409-A)**  
(I Incorporated in Malaysia)

**UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME  
FOR THE FINANCIAL PERIOD ENDED 31 DECEMBER 2025**

	Individual Quarter		6 months ended	
	Current Year Quarter	Preceding Year Quarter	Current Year To Date	Preceding Year Corresponding Period
	31/12/2025 RM'000	31/12/2024 RM'000	31/12/2025 RM'000	31/12/2024 RM'000
Revenue	103,497	80,426	203,974	162,393
Other operating income	1,356	1,075	3,152	1,954
Inventories and consumables	(37,922)	(26,258)	(74,632)	(52,463)
Staff costs	(28,516)	(29,421)	(57,724)	(58,215)
Other operating expenses	(18,481)	(16,619)	(37,553)	(31,703)
Depreciation and amortisation	(9,401)	(8,622)	(18,748)	(15,848)
Interest income	750	1,320	1,430	2,660
Finance costs	(1,947)	(2,394)	(3,996)	(4,812)
<b>Profit / (Loss) before taxation</b>	<b>9,336</b>	<b>(493)</b>	<b>15,903</b>	<b>3,966</b>
Taxation	(2,776)	(454)	(4,930)	(1,977)
<b>Profit / (Loss) for the financial period, representing total  comprehensive income / (loss) (net of tax) for the financial period</b>	<b>6,560</b>	<b>(947)</b>	<b>10,973</b>	<b>1,989</b>
<b>Profit / (Loss) for the financial period, representing total  comprehensive income / (loss) (net of tax) for the financial period  attributable to:-</b>				
<b>Owners of the parent</b>	<b>6,560</b>	<b>(947)</b>	<b>10,973</b>	<b>1,989</b>
<b>Profit / (Loss) per ordinary share attributable  to the owners of the parent (sen)</b>				
Basic / Diluted	0.38	(0.05)	0.63	0.11

The unaudited condensed consolidated statement of comprehensive income should be read in conjunction with the accompanying explanatory notes attached to the interim financial statements.

**TMC LIFE SCIENCES BERHAD**  
**Company no. 200301021989 (624409-A)**  
(Iincorporated in Malaysia)

**UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY**  
**FOR THE FINANCIAL PERIOD ENDED 31 DECEMBER 2025**

	Attributable to owners of the parent		Total equity RM'000
	Non-distributable	Distributable	
	Share capital RM'000	Share options reserve RM'000	Retained profits RM'000
<b>Balance at 1 July 2025</b>	625,986	-	227,057
Profit for the financial period, representing total comprehensive income (net of tax) for the financial period	-	-	10,973
<b>Transaction with owners</b>			
Dividend paid	-	-	(3,245)
<b>Balance at 31 December 2025</b>	<b>625,986</b>	<b>-</b>	<b>234,785</b>
<b>Balance at 1 July 2024</b>	625,986	1,316	260,732
Profit for the financial year, representing total comprehensive income (net of tax) for the financial year	-	-	3,606
<b>Transactions with owners</b>			
Share options granted under ESOS	-	19	-
Transfer within reserve for ESOS forfeited	-	(1,335)	1,335
Dividend paid	-	-	(38,616)
<b>Total transactions with owners</b>	<b>-</b>	<b>(1,316)</b>	<b>(37,281)</b>
<b>Balance at 30 June 2025</b>	<b>625,986</b>	<b>-</b>	<b>227,057</b>
			<b>853,043</b>

The unaudited condensed consolidated statement of changes in equity should be read in conjunction with the audited financial statements for the financial year ended 30 June 2025 and the accompanying explanatory notes attached to the interim financial statements.

**TMC LIFE SCIENCES BERHAD**  
**Company no. 200301021989 (624409-A)**  
(Iincorporated in Malaysia)

**UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION**  
**AS AT 31 DECEMBER 2025**

	As At 31/12/2025 Unaudited RM'000	As At 30/06/2025 Audited RM'000
<b>Non-current assets</b>		
Property, plant and equipment	716,290	725,778
Intangible assets	198,565	201,192
Investment property	2,010	2,039
Deferred tax assets	701	700
Total non-current assets	<u>917,566</u>	<u>929,709</u>
<b>Current assets</b>		
Inventories	17,634	15,908
Trade and other receivables	64,053	65,600
Tax recoverable	6,999	11,409
Cash and bank balances	112,896	109,564
Total current assets	<u>201,582</u>	<u>202,481</u>
<b>TOTAL ASSETS</b>	<u>1,119,148</u>	<u>1,132,190</u>
<b>Current liabilities</b>		
Contract liabilities	527	519
Trade and other payables	60,552	69,286
Borrowings	45,108	38,047
Lease liabilities	1,636	1,901
Income tax payable	5	559
Total current liabilities	<u>107,828</u>	<u>110,312</u>
<b>NET CURRENT ASSETS</b>	<u>93,754</u>	<u>92,169</u>
<b>Non-current liabilities</b>		
Contract liabilities	335	357
Borrowings	118,980	141,426
Lease liabilities	1,321	1,598
Provision	755	739
Deferred tax liabilities	29,158	24,715
Total non-current liabilities	<u>150,549</u>	<u>168,835</u>
<b>TOTAL LIABILITIES</b>	<u>258,377</u>	<u>279,147</u>
<b>NET ASSETS</b>	<u>860,771</u>	<u>853,043</u>
<b>Represented by:</b>		
<b>Equity attributable to owners of the parent</b>		
Share capital	625,986	625,986
Retained profits	234,785	227,057
<b>TOTAL EQUITY</b>	<u>860,771</u>	<u>853,043</u>
Net assets per share (RM)	<u>0.49</u>	<u>0.49</u>

The unaudited condensed consolidated statement of financial position should be read in conjunction with the audited financial statements for the financial year ended 30 June 2025 and the accompanying explanatory notes attached to the interim financial statements.

**UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS**  
**FOR THE FINANCIAL PERIOD ENDED 31 DECEMBER 2025**

	Current Year To Date	Preceding Year Corresponding Period
	31/12/2025 RM'000	31/12/2024 RM'000
<b>Cash flows from operating activities</b>		
Profit before tax	15,903	3,966
Adjustments for :-		
Non-cash items	19,221	16,398
Interest expense	3,996	4,812
Interest income	(1,430)	(2,660)
Operating profit before changes in working capital	<hr/> 37,690	<hr/> 22,516
Changes in working capital		
Net change in current assets	(649)	(4,503)
Net change in trade and other payables and contract liabilities	(8,241)	(113)
Cash generated from operations	<hr/> 28,800	<hr/> 17,900
Interest paid	(3,881)	(4,719)
Net income tax refunded / (paid)	3,370	(1,079)
<b>Net cash flows generated from operating activities</b>	<hr/> 28,289	<hr/> 12,102
<b>Cash flows from investing activities</b>		
Acquisition of property, plant and equipment	(5,554)	(20,952)
Acquisition of intangible assets	(820)	(449)
Proceeds from disposal of property, plant and equipment	3	-
Withdrawal of deposits placed with:-		
- financial institutions with original maturity of more than three (3) months	26,802	20,560
- deposits pledged	90	210
Interest received	1,430	2,660
<b>Net cash flows generated from investing activities</b>	<hr/> 21,951	<hr/> 2,029
<b>Cash flows used in financing activities</b>		
Dividend paid	(3,245)	(38,616)
Payment of lease liabilities	(1,278)	(1,180)
Repayment of term loans	(15,053)	(7,550)
Repayment of hire purchase	(441)	(441)
<b>Net cash flows used in financing activities</b>	<hr/> (20,017)	<hr/> (47,787)
<b>Net increase/(decrease) in cash &amp; cash equivalents</b>	<hr/> 30,223	<hr/> (33,656)
<b>Cash &amp; cash equivalents at beginning of the financial period</b>	60,822	107,511
<b>Cash &amp; cash equivalents at end of the financial period</b>	<hr/> 91,045	<hr/> 73,855
<b>Cash &amp; cash equivalents at end of the financial period</b>		
Cash at banks and on hand	52,819	51,079
Deposits with licenced banks	60,077	83,066
	<hr/> 112,896	<hr/> 134,145
Less: Deposits with licensed banks (for more than 3 months)	(17,835)	(56,300)
Deposit pledged to a licenced bank	(1,556)	(1,530)
Cash restricted in use	(2,460)	(2,460)
	<hr/> 91,045	<hr/> 73,855

The unaudited condensed consolidated statement of cash flows should be read in conjunction with the accompanying explanatory notes attached to the interim financial statements.

**NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT  
FOR THE FINANCIAL PERIOD ENDED 31 DECEMBER 2025**

**A EXPLANATORY NOTES PURSUANT TO MALAYSIAN FINANCIAL REPORTING  
STANDARDS ("MFRS")**

**A1 BASIS OF PREPARATION**

The interim financial report is unaudited and has been prepared in compliance with Malaysian Financial Reporting Standards ("MFRS") 134 - Interim Financial Reporting and paragraph 9.22 of the Main Market Listing Requirements of Bursa Malaysia Securities Berhad.

The interim financial report should be read in conjunction with the audited financial statements of TMC Life Sciences Berhad and its subsidiaries ("the Group") for the financial year ended 30 June 2025. The explanatory notes attached to the interim financial statements provide an explanation of events and transactions that are significant for understanding the changes in the financial position of the Group since the financial year ended 30 June 2025, and changes in financial performance since the preceding year corresponding period.

The accounting policies and methods of computations used in the preparation of the financial statements are consistent with those adopted in the audited financial statements for the financial year ended 30 June 2025, except for the adoption of the new, revised and amendments to MFRS and IC Interpretations effective as of 1 January 2025 as issued by the Malaysian Accounting Standards Board, which does not have any significant impact on the financial statements of the Group.

**A2 SEASONALITY OR CYCLICALITY OF OPERATIONS**

The Group's business is typically impacted during festive and holiday periods when a decrease in patient load is anticipated.

**A3 UNUSUAL ITEMS AFFECTING ASSETS, LIABILITIES, EQUITY, NET INCOME OR CASH FLOWS**

There were no material items or events that arose, which affected assets, liabilities, equity, net income or cash flows that are unusual by reasons of their nature, size or incidence.

**A4 CHANGE IN ACCOUNTING ESTIMATES**

There were no material changes in the nature and amount of estimates reported that have a material effect in the current financial quarter under review.

**A5 ISSUANCE AND REPAYMENT OF DEBT AND EQUITY SECURITIES**

There were no issuance, cancellation, repurchases, resale and repayment of debt and equity securities in the current financial quarter under review.

## A6 DIVIDEND PAID

During the financial period ended 31 December 2025, the Company paid a final single tier dividend of 0.1863 sen per ordinary share on 1,741,882,393 ordinary shares, amounting to RM3,245,111 in respect of the financial year ended 30 June 2025.

## A7 SEGMENTAL INFORMATION

The Group operates mainly in Malaysia and is involved in the healthcare sector which includes providing specialist healthcare services in its multi disciplinary tertiary hospital and fertility centres.

## A8 MATERIAL EVENT SUBSEQUENT TO THE END OF THE INTERIM REPORTING PERIOD

There was no material event subsequent to 31 December 2025 and up to the date of this report that would likely affect substantially the results of the operations of the Group.

## A9 CHANGES IN THE COMPOSITION OF THE GROUP

There were no changes in the composition of the Group during the current quarter under review.

## A10 CONTINGENT LIABILITIES OR CONTINGENT ASSETS

Financial guarantees	31/12/2025 RM'000	30/06/2025 RM'000
<u>Unsecured</u>		
Corporate guarantees given to licensed bank for banking facility granted to wholly-owned subsidiaries	164,088	179,473
Letter of guarantee given to suppliers	4,596	9,225
	<u>168,684</u>	<u>188,698</u>

## A11 CAPITAL COMMITMENTS

The amount of commitments for capital expenditure is as follows:

Approved and contracted for	31/12/2025 RM'000	30/06/2025 RM'000
	<u>38,428</u>	<u>29,581</u>

## A12 SIGNIFICANT RELATED PARTY TRANSACTIONS

There were no significant related party transactions during the quarter under review.

**TMC LIFE SCIENCES BERHAD**  
**Company no. 200301021989 (624409-A)**  
(I Incorporated in Malaysia)

**NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT  
FOR THE FINANCIAL PERIOD ENDED 31 DECEMBER 2025**

**B ADDITIONAL INFORMATION REQUIRED BY BURSA MALAYSIA SECURITIES BERHAD ("BURSA SECURITIES")**

**B1 REVIEW OF THE PERFORMANCE OF THE GROUP**

**Analysis of performance**

**Review of results for the financial quarter (3 months ended 31 December 2025 versus 3 months ended 31 December 2024)**

	3 months ended	31/12/2025	31/12/2024
	RM'000	RM'000	RM'000
Revenue	103,497	80,426	80,426
Profit / (Loss) before taxation	9,336	(493)	(493)

For the quarter ended 31 December 2025, the Group recorded revenue of RM103.5 million and profit before taxation of RM9.3 million, representing an increase of 29% and more than 100% respectively, compared to the previous corresponding quarter. The increase in profit before taxation was due to contribution from our various specialties and cost efficiency initiatives at Thomson Hospital Kota Damansara ("THKD").

**Review of results for the financial period (6 months ended 31 December 2025 versus 6 months ended 31 December 2024)**

	6 months ended	31/12/2025	31/12/2024
	RM'000	RM'000	RM'000
Revenue	203,974	162,393	162,393
Profit before taxation	15,903	3,966	3,966

For the financial period ended 31 December 2025, the Group reported a 26 % increase in revenue to RM204 million and more than 100% increase in profit before taxation to RM15.9 million, compared to the same period ended 31 December 2024. The improvement in profit before taxation attributable to the rebound in hospital revenue and cost efficiency initiatives at THKD.

**Material factors affecting the earnings and / or revenue of the Group**

The material factors that affect the earnings and / or revenue of the Group are the successful recruitment of healthcare professionals in our facilities, additional bed capacity and additional services offered by the Group, higher case intensity handled, and continuous marketing effort to boost local and international branding.

**B2 MATERIAL CHANGE IN PROFIT BEFORE TAX AS COMPARED WITH IMMEDIATE PRECEDING QUARTER**

**(3 months ended 31 December 2025 versus 3 months ended 30 September 2025)**

	3 months ended	31/12/2025	30/09/2025
	RM'000	RM'000	RM'000
Revenue	103,497	100,477	100,477
Profit before taxation	9,336	6,567	6,567

Compared to the immediate preceding quarter ended 30 September 2025, revenue increased while profit before taxation rose by 42%. The profit growth was driven by improved cost efficiencies.

### **B3 PROSPECTS FOR THE FINANCIAL YEAR ENDING 30 JUNE 2026**

Evolving dynamics in the reimbursement environment continue to influence the private healthcare landscape, as payors place greater emphasis on affordability, efficiency and value. The Group is adopting a balanced and constructive approach in its engagements with payors, while diversifying revenue streams and driving cost efficiencies.

The Group remains optimistic about its growth trajectory. This is supported by increased capacity and ongoing expansion across key specialties at THKD. The Group continues to broaden its customer mix by attracting more corporate and international patients, while strengthening collaborative partnerships with insurers to support mutually sustainable growth.

### **B4 VARIANCE ON PROFIT FORECAST/PROFIT GUARANTEE**

There is no profit forecast or profit guarantee for the financial period ended 31 December 2025.

### **B5 TAXATION**

	Individual quarter		6 months ended	
	31/12/2025 RM'000	31/12/2024 RM'000	31/12/2025 RM'000	31/12/2024 RM'000
In respect of current quarter / financial period				
Current tax expense	305	689	486	1,293
Deferred tax expense	2,471	(235)	4,444	684
	<u>2,776</u>	<u>454</u>	<u>4,930</u>	<u>1,977</u>

Tax provision during the current quarter refers to recognition of tax expense for profit making subsidiaries.

### **B6 STATUS OF CORPORATE PROPOSAL**

There are no corporate proposals announced but not completed as at 2 February 2026, being the latest practicable date which shall not be earlier than 7 days from the date of this quarterly report.

### **B7 BORROWINGS**

The Group's borrowings are as follows:-

	Long Term RM'000	Short Term RM'000	Total RM'000
As at 31 December 2025			
Secured - Denominated in Ringgit Malaysia	<u>118,980</u>	<u>45,108</u>	<u>164,088</u>
As at 30 June 2025			
Secured - Denominated in Ringgit Malaysia	<u>141,426</u>	<u>38,047</u>	<u>179,473</u>

Included in the Group's borrowings is industrial hire purchase of NIL as at the reporting date (30 June 2025: RM442,000).

### **B8 MATERIAL LITIGATION**

There was no material litigation as at the date of this report.

## B9 DIVIDENDS

The Board does not recommend any dividend for the current quarter under review (previous year corresponding period ended 31 December 2024: NIL)

## B10 EARNINGS PER SHARE (EPS)

	Individual quarter		6 months ended	
	31/12/2025	31/12/2024	31/12/2025	31/12/2024
Basic / Diluted EPS				
Net profit / (loss) attributable to owners of the parent (RM'000)	6,560	(947)	10,973	1,989
Weighted average number of ordinary shares in issue ('000)	1,741,882	1,741,882	1,741,882	1,741,882
EPS (sen)				
- Basic / Diluted	0.38	(0.05)	0.63	0.11

## B11 AUDITORS' REPORT ON PRECEDING ANNUAL FINANCIAL STATEMENTS

The audit report of the preceding annual financial statements was unqualified.

## B12 NOTE TO STATEMENT OF COMPREHENSIVE INCOME

	Individual quarter		6 months ended	
	31/12/2025	31/12/2024	31/12/2025	31/12/2024
	RM'000	RM'000	RM'000	RM'000
Interest income	750	1,320	1,430	2,660
Interest expense	(1,944)	(2,390)	(3,991)	(4,804)
Unwinding of discount on provision for restoration	(3)	(4)	(5)	(8)
Depreciation of property, plant and equipment, investment property and right-of-use assets	(7,665)	(6,895)	(15,302)	(13,387)
Amortisation of intangible assets	(1,736)	(1,727)	(3,446)	(2,461)
Impairment loss on receivables	(210)	(210)	(420)	(420)
Fair value charges on share options granted under ESOS	-	(5)	-	(10)
Property, plant and equipment written off	-	(7)	(16)	(12)
Gain on disposal of property, plant and equipment	-	-	3	-
Gain on derecognition of lease liability	8	-	8	-
Inventories written off	(25)	(81)	(48)	(108)

## B13 DERIVATIVE FINANCIAL INSTRUMENTS

The Group did not enter into any derivative financial instruments which were outstanding as at 31 December 2025 and 30 June 2025.

## B14 AUTHORISED FOR ISSUE

The condensed consolidated interim financial statements were authorised for issue by the Board of Directors in accordance with a resolution of the Directors on 9 February 2026.